2023年7月14日

西奈加速器歡迎十個健康技術員公司全球第九類加速器。這些企業正在建造各種各樣的醫療解決方案監控設備對於膿毒症,心力衰竭和中風虛擬現實遊戲旨在幫助孩子管理在醫療過程痛苦和焦慮。在三個月的計劃,公司領導從西奈研究者獲得實踐經驗和指導,管理員,和臨床醫生,開發和完善他們的產品和解決方案的實際應用。隨著個性化指導,每個公司將獲得100000美元的投資從西奈。和三個月的項目完成後,公司領導人將與觀眾分享他們的進步的投資者,導師,潛在客戶,和新聞媒體成員演示的一天。第九西奈加速器類包括:- 52北-劍橋,英國的公司52北健康發展醫院外的醫療設備,患者可以使用監控粒細胞減少性膿毒症的風險,危及生命的並發症的化療。Neutrocheck設備提供家庭測試使用血液從一個小針孔。- Acorai -斯德哥爾摩,瑞典公司Acorai為心髒衰竭開發設備管理通過無創性心髒內的壓力監測,幫助減少住院和再入院。Acorai心髒監測結合地震、音頻、視覺、和電子傳感器,實時捕捉和分析數據使用機器學習。 — Alva Health – New Haven, Connecticut-based Alva Health develops wearable monitoring devices for early stroke detection. The system uses machine learning to monitor the onset of hemiparesis (paralysis on one side of the body). When the system detects a stroke, the device notifies the user immediately. If there is no response from the user, the device can connect users with emergency responders. — CARI Health – San Diego, California-based CARI Health develops a remote medication monitor to enable personalized dosing and real-time medication adherence monitoring. CARI’s solution combines proprietary core sensing technology with just-in-time intervention software, mobile apps, data, and AI to detect medication levels in real-time. — equalityMD – Richmond, Virginia-based equalityMD develops a community-centric platform for LGBTQ+ patients to share and connect with others. The platform also provides telehealth services by connecting to clinicians, enabling LGBTQ+ patients to share their experiences and foster a true sense of community around health and wellness. — Machine Medicine – London, U.K.-based Machine Medicine develops a platform that helps researchers capture and assess motor functioning in patients with neuromodulation devices. KELVIN (the software component) enables anyone to do a motor assessment remotely via their smartphone, allowing faster and more frequent patient monitoring. — Paperplane Therapeutics – Quebec, Canada-based Paperplane Therapeutics designs therapeutic virtual reality video games to improve pain and anxiety management in children undergoing various medical treatments or procedures. — Predicta Med – Ramat Gan, Israel-based Predicta Med develops a solution for early detection and treatment selection for undiagnosed autoimmune diseases. Predicta Med’s deep learning engine aggregates electronic medical records and claims data. It enriches and analyzes this data to identify patients at risk of autoimmune diseases and provide actionable insights for optimal intervention. — RCE.ai – Carlsbad, California-based RCE Technologies develops a noninvasive device that monitors cardiac proteins in the blood, empowering emergency medicine physicians and cardiologists to assess patients presenting with chest pain early. — TestDynamics – Austin, Texas-based TestDynamics develops a platform that offers hospitals and physicians one-stop, intelligent access to a wide range of AI models for medical imaging. It aims to improve patient care outcomes, reduce healthcare costs, and lower malpractice risk. KEY QUOTES: “I’m excited to welcome these innovative teams from around the globe who are developing new technologies which have the promise to enhance the delivery of efficient and cost-effective patient care.” — James Laur, JD, vice president of Intellectual Property, managing director of Cedars-Sinai Technology Ventures, and one of the accelerator’s founders “The provision of strategic and operational insights at the outset of development plays a pivotal role in driving healthcare innovations, and each accelerator class brings that opportunity to the Cedars-Sinai community. With our next class, we are looking forward to continuing to transform healthcare and research here in Los Angeles and beyond.” — Nirdesh K. Gupta, Ph.D., managing director of Cedars-Sinai Technology Ventures Trending on Pulse 2.0